Drugs / Norwalk VLP Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00806962 | Nov 2008 → Oct 2009 | norovirus infectious disease | LigoCyte Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00973284 | Aug 2009 → Apr 2010 | gastroenteritis, norovirus infectious disease | Takeda | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norwalk VLP vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00973284 ↗ |
| Known as | Norwalk virus-like particle (VLP) vaccine | “The drug being tested in this study is called intranasal Norwalk virus-like particle (VLP) vaccine.” NCT00973284 ↗ |
| Modality | Vaccine | “virus-like particle (VLP) vaccine” PMID 20979455 ↗ Oct 2010 |
| Route | Intranasal | “intranasal, 50mcg, 2 doses--21 days apart” NCT00806962 ↗ |